{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T18:04:19Z","timestamp":1785175459334,"version":"3.55.0"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Biological therapies are critical in the management of Immune-Mediated Diseases (IMDs), yet their use is linked to adverse effects, including an elevated risk of Tuberculosis (TB), a significant health issue in endemic regions like Brazil. This study aimed to assess the incidence of TB among patients with IMDs in rheumatology, gastroenterology, and dermatology who received biological therapy in Pernambuco between 2013 and 2023. A total of 8,623 patients were analyzed, with 90.7% diagnosed with rheumatologic diseases, 5.6% with gastroenterological diseases, and 3.7% with psoriasis. In the descriptive analysis, frequency distributions and medians with interquartile ranges were reported, and Relative Risk (RR) was calculated to compare tuberculosis occurrence across IMD groups. The overall TB incidence was 2.1%, highest in gastroenterological patients (4.7%) compared to rheumatologic (2.0%) and psoriasis patients (1.3%) with a risk ratio (RR) of 2.4 for the group of gastroenterological diseases (p\u2009&lt;\u20090.001). No significant differences in TB frequency were detected before (1.16%) or during (0.97%) the use of biological therapy, nor among drug classes, except for a slightly higher incidence with infliximab (2.6%). The absence of differences between the other anti-Tumor Necrosis Factor (anti-TNF) drugs and other cytokine inhibitors suggests that TB incidence might be influenced by environmental exposure in endemic regions. Pulmonary TB was the predominant form (80.8%), and pleural TB emerged as the most frequent extrapulmonary manifestation. The results underscore the need for extensive regional studies to elucidate TB risks in IMD patients and refine treatment guidelines for immunobiological therapies.<\/jats:p>","DOI":"10.1371\/journal.pone.0353691","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:33:02Z","timestamp":1785173582000},"page":"e0353691","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence of tuberculosis in patients with immune-mediated diseases undergone biological therapy: A 10-year observational study in a high-burden region of northeastern Brazil"],"prefix":"10.1371","volume":"21","author":[{"given":"Rosinete Maria","family":"dos Santos Guimar\u00e3es","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Diniz","family":"Lopes Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulisses Ramos","family":"Montarroyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Santos","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaqueline","family":"Alves da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linaldo Francisco Silva","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irassandra Rooze Pereira Uch\u00f4a Cavalcanti","family":"de Aquino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Dhalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-1564","authenticated-orcid":true,"given":"Edmundo Pessoa","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5963-8178","authenticated-orcid":true,"given":"Carlos Alexandre Antunes de","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"pone.0353691.ref001","volume-title":"Global Tuberculosis, vol. t\/malaria\/, no","author":"World Health Organization (WHO)","year":"2023"},{"key":"pone.0353691.ref002","first-page":"100","author":"Brazil. Ministry of Health Secretariat of Health and Environmental Surveillance","year":"2024","journal-title":"Special Epidemiological Bulletin \u2013 Tuberculosis 2024"},{"key":"pone.0353691.ref003","author":"M. of H. Brazil","year":"2023"},{"issue":"3","key":"pone.0353691.ref004","doi-asserted-by":"crossref","first-page":"340","DOI":"10.14309\/ajg.0000000000000527","article-title":"Risk of tuberculosis in patients with inflammatory bowel disease on infliximab or adalimumab is dependent on the local disease burden of tuberculosis: a systematic review and meta-analysis","volume":"115","author":"S Kedia","year":"2020","journal-title":"Off J Am J Gastroenterol"},{"issue":"11","key":"pone.0353691.ref005","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/jdv.12011","article-title":"Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry","volume":"27","author":"AI S\u00e1nchez-Moya","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"pone.0353691.ref006","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/medicina56080392","article-title":"Incidence of tuberculosis in inflammatory rheumatic diseases: results from a lithuanian retrospective cohort study","volume":"56","author":"D Miltinien\u0117","year":"2020","journal-title":"Medicina (Kaunas)"},{"key":"pone.0353691.ref007","doi-asserted-by":"crossref","first-page":"17562848231179871","DOI":"10.1177\/17562848231179871","article-title":"Active tuberculosis in inflammatory bowel disease patients: a case-control study","volume":"16","author":"M Freitas Cardoso de Azevedo","year":"2023","journal-title":"Ther Adv Gastroenterol"},{"key":"pone.0353691.ref008","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1756-185X.12539","article-title":"Risk of tuberculosis, serious infection and lymphoma with disease\u2010modifying biologic drugs in rheumatoid arthritis patients in Taiwan","volume":"17","author":"Y Chiu","year":"2014","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"pone.0353691.ref009","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/rheumatology\/key364","article-title":"Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region","volume":"58","author":"X Wang","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"pone.0353691.ref010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224963","article-title":"A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment","volume":"14","author":"NS Sartori","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"pone.0353691.ref011","article-title":"The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: a 15-year real world experience in Taiwan","volume":"12","author":"CH Lim","year":"2017","journal-title":"PLoS One"},{"key":"pone.0353691.ref012","first-page":"477","article-title":"Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitora\u00e7\u00e3o de Terapias Biol\u00f3gicas \u2013 BiobadaBrasil)","volume":"57","author":"CL Yonekura","year":"2017","journal-title":"Rev Bras Reumatol"},{"issue":"1","key":"pone.0353691.ref013","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13075-022-02842-6","article-title":"Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013\u20132018","volume":"24","author":"SM Jung","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"pone.0353691.ref014","doi-asserted-by":"crossref","first-page":"101533","DOI":"10.1016\/j.nmni.2024.101533","article-title":"Risk of tuberculosis disease in patients receiving TNF-\u03b1 antagonist therapy: a meta-analysis of randomized controlled trials","volume":"62","author":"F Khelghati","year":"2024","journal-title":"New Microbes New Infect"},{"issue":"7","key":"pone.0353691.ref015","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1093\/rheumatology\/kead515","article-title":"Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter?","volume":"63","author":"BSRBR-RA Contributors Group","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"pone.0353691.ref016","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.1038\/s41598-017-06899-1","article-title":"Active tuberculosis incidence and characteristics in patients treated with tumor necrosis factor antagonists according to latent tuberculosis infection","volume":"7","author":"EH Lee","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"pone.0353691.ref017","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1513\/AnnalsATS.201608-647OC","article-title":"Efficacy of treatment for latent tuberculosis in patients undergoing treatment with a tumor necrosis factor antagonist","volume":"14","author":"J Lee","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"pone.0353691.ref018","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5217\/ir.2018.16.1.4","article-title":"Asian organization for Crohn\u2019s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment","volume":"16","author":"DI Park","year":"2018","journal-title":"Intest Res"},{"key":"pone.0353691.ref019","author":"M. of H. Brazil","year":"2025"},{"key":"pone.0353691.ref020","doi-asserted-by":"crossref","unstructured":"Barros AJD, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. 2003;13:1\u201313.","DOI":"10.1186\/1471-2288-3-21"},{"issue":"6","key":"pone.0353691.ref021","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease","volume":"15","author":"T Kucharzik","year":"2021","journal-title":"J Crohn\u2019s Colitis"},{"issue":"1","key":"pone.0353691.ref022","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5152\/eurjrheum.2016.16100","article-title":"Vaccination recommendations for adult patients with rheumatic diseases","volume":"3","author":"MD Tanr\u0131\u00f6ver","year":"2016","journal-title":"Eur J Rheumatol"},{"issue":"1","key":"pone.0353691.ref023","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"V Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"pone.0353691.ref024","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/apt.13851","article-title":"Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea","volume":"45","author":"SN Hong","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"pone.0353691.ref025","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.cgh.2007.04.007","article-title":"Risk for active tuberculosis in inflammatory bowel disease patients","volume":"5","author":"FN Aberra","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"pone.0353691.ref026","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1038\/ajg.2009.322","article-title":"Adverse events associated with common therapy regimens for moderate-to-severe Crohn\u2019s disease","volume":"104","author":"J Marehbian","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"pone.0353691.ref027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1546-0096-12-45","article-title":"Immunity against Mycobacterium tuberculosis and the risk of biologic anti-TNF-\u03b1 reagents","volume":"12","author":"K Yasui","year":"2014","journal-title":"Pediatr Rheumatol"},{"issue":"7","key":"pone.0353691.ref028","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"F Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"4","key":"pone.0353691.ref029","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/medicina60040579","article-title":"Tuberculosis and nontuberculous mycobacterial infections in patients with spondyloarthritis: a population-based study","volume":"60","author":"J Yang","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"15","key":"pone.0353691.ref030","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"J Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"pone.0353691.ref031","volume-title":"Tuberculosis surveillance and monitoring in Europe","author":"E. C. for D. P. A. C. ECDC","year":"2023"},{"key":"pone.0353691.ref032","doi-asserted-by":"crossref","unstructured":"Souza R, et al. Space-time scan of tuberculosis indicators in Northeast Brazil: an ecological and time-series study over 20 years (2001-2020). 2025.","DOI":"10.1186\/s12889-025-24307-6"},{"key":"pone.0353691.ref033","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/CEG.S411936","article-title":"A multicentre study of the clinical and epidemiological profile of inflammatory bowel disease in northeast Brazil","author":"CAA de Brito","year":"2023","journal-title":"Clin Exp Gastroenterol"},{"key":"pone.0353691.ref034","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"CA Lamb","year":"2019","journal-title":"Gut"},{"issue":"7","key":"pone.0353691.ref035","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/07853890.2014.941919","article-title":"Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials","volume":"46","author":"R Lorenzetti","year":"2014","journal-title":"Ann Med"},{"issue":"1","key":"pone.0353691.ref036","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"JS Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"pone.0353691.ref037","first-page":"281","article-title":"Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides","volume":"55","author":"LMH da Mota","year":"2015","journal-title":"Rev Bras Reumatol"},{"issue":"2","key":"pone.0353691.ref038","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000222431","article-title":"Tuberculin skin test overestimates tuberculosis hypersensitivity in adult patients with psoriasis","volume":"219","author":"G Tsiouri","year":"2009","journal-title":"Dermatology"},{"issue":"4","key":"pone.0353691.ref039","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2340\/00015555-1106","article-title":"Patients with psoriasis are more likely to be treated for latent tuberculosis infection prior to biologics than patients with inflammatory bowel disease","volume":"91","author":"ID Bassukas","year":"2011","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"pone.0353691.ref040","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/jid.2011.139","article-title":"Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin","volume":"131","author":"HJ Bovenschen","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"9","key":"pone.0353691.ref041","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies","volume":"78","author":"DG McGonagle","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"pone.0353691.ref042","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41584-024-01107-7","article-title":"Joint-specific memory, resident memory T cells and the rolling window of opportunity in arthritis","volume":"20","author":"MH Chang","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"pone.0353691.ref043","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2012.12.966","article-title":"Association between traditional systemic antipsoriatic drugs and tuberculosis risk in patients with psoriasis with or without psoriatic arthritis: results of a nationwide cohort study from Taiwan","volume":"69","author":"Y-J Chen","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"pone.0353691.ref044","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.semarthrit.2018.03.018","article-title":"High rates of tuberculin skin test positivity due to methotrexate therapy: false positive results?","volume":"48","author":"M Arias-Guill\u00e9n","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"pone.0353691.ref045","article-title":"TST conversions and systemic interferon-gamma increase after methotrexate introduction in psoriasis patients","volume":"15","author":"VLS de Medeiros","year":"2020","journal-title":"PLoS One"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0353691","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:33:10Z","timestamp":1785173590000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0353691"}},"subtitle":[],"editor":[{"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0353691","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]}}}